Tag: ILMN

Illumina, Inc. with ticker code (ILMN) have now 22 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The range between the high target price and low target price is between $249.00 and $100.00 suggesting an average Analsyt target price of $146.82. Given that the stocks previous close was at $109.07 this is indicating there is a potential upside of 34.6%. The day 50 moving average is $114.54 and the 200 day moving average is $126.42. The market cap for the company is 17.22B. The stock price is currently at: $108.10 USD

The potential market cap would be $23,180,423,334 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of -, revenue per share of $28.39 and a -0.5% return on assets.

Illumina, Inc. is a provider of sequencing- and array-based solutions for genetic and genomic analysis. The Company operates through two segments: Core Illumina and GRAIL. Its Core Illumina segment offers products and services that serve customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. Its GRAIL segment is a healthcare company focused on early detection of multiple cancers. Its portfolio of integrated sequencing and microarray systems, consumables, and analysis tools is designed to accelerate and simplify genetic analysis. Its BaseSpace Informatics Suite integrates directly with its sequencing instruments, allowing customers to manage their biological sample and sequencing runs, process and analyze the raw genomic data, and derive results. Its BeadArray technology combines microscopic beads and a substrate in a proprietary manufacturing process to produce arrays that can perform various assays simultaneously.

Illumina, Inc. with ticker code (ILMN) have now 22 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The target price High/Low ranges between $253.00 and $100.00 suggesting an average Analsyt target price of $147.91. Given that the stocks previous close was at $113.70 this would imply there is now a potential upside of 30.1%. The 50 day moving average now sits at $116.87 and the 200 day MA is $127.99. The total market capitalization for the company now stands at 17.49B. The stock price is currently at: $109.82 USD

The potential market cap would be $22,758,009,212 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of -, revenue per share of $28.39 and a -0.5% return on assets.

Illumina, Inc. is a provider of sequencing- and array-based solutions for genetic and genomic analysis. The Company operates through two segments: Core Illumina and GRAIL. Its Core Illumina segment offers products and services that serve customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. Its GRAIL segment is a healthcare company focused on early detection of multiple cancers. Its portfolio of integrated sequencing and microarray systems, consumables, and analysis tools is designed to accelerate and simplify genetic analysis. Its BaseSpace Informatics Suite integrates directly with its sequencing instruments, allowing customers to manage their biological sample and sequencing runs, process and analyze the raw genomic data, and derive results. Its BeadArray technology combines microscopic beads and a substrate in a proprietary manufacturing process to produce arrays that can perform various assays simultaneously.

Illumina, Inc. which can be found using ticker (ILMN) now have 21 analysts in total covering the stock. The consensus rating is pointing to ‘hold’. The target price High/Low ranges between $253.00 and $100.00 calculating the mean target share price we have $150.34. (at the time of writing). Given that the stocks previous close was at $104.28 this now indicates there is a potential upside of 44.2%. The 50 day MA is $119.55 and the 200 moving average now moves to $129.41. The market cap for the company is 16.47B. The stock price is currently at: $103.37 USD

The potential market cap would be $23,740,170,370 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of -, revenue per share of $28.39 and a -0.5% return on assets.

Illumina, Inc. is a provider of sequencing- and array-based solutions for genetic and genomic analysis. The Company operates through two segments: Core Illumina and GRAIL. Its Core Illumina segment offers products and services that serve customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. Its GRAIL segment is a healthcare company focused on early detection of multiple cancers. Its portfolio of integrated sequencing and microarray systems, consumables, and analysis tools is designed to accelerate and simplify genetic analysis. Its BaseSpace Informatics Suite integrates directly with its sequencing instruments, allowing customers to manage their biological sample and sequencing runs, process and analyze the raw genomic data, and derive results. Its BeadArray technology combines microscopic beads and a substrate in a proprietary manufacturing process to produce arrays that can perform various assays simultaneously.

Illumina, Inc. with ticker code (ILMN) have now 21 market analysts covering the stock. The analyst consensus now points to a rating of ‘hold’. The range between the high target price and low target price is between $253.00 and $100.00 with the average share target price sitting at $150.96. (at the time of writing). Given that the stocks previous close was at $111.07 and the analysts are correct then there would likely be a percentage uptick in value of 35.9%. Also worth taking note is the 50 day moving average now sits at $124.58 and the 200 day moving average is $132.85. The total market capitalization for the company now stands at 17.29B. The stock price for the company is currently is currently $108.53 USD

[stock_market_widget type=”chart” template=”basic” color=”green” assets=”ILMN” range=”6mo” interval=”1d” axes=”true” cursor=”true” api=”yf”]

The potential market cap would be $23,497,988,791 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of -, revenue per share of $28.39 and a -0.5% return on assets.

Illumina, Inc. is a provider of sequencing- and array-based solutions for genetic and genomic analysis. The Company operates through two segments: Core Illumina and GRAIL. Its Core Illumina segment offers products and services that serve customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. Its GRAIL segment is a healthcare company focused on early detection of multiple cancers. Its portfolio of integrated sequencing and microarray systems, consumables, and analysis tools is designed to accelerate and simplify genetic analysis. Its BaseSpace Informatics Suite integrates directly with its sequencing instruments, allowing customers to manage their biological sample and sequencing runs, process and analyze the raw genomic data, and derive results. Its BeadArray technology combines microscopic beads and a substrate in a proprietary manufacturing process to produce arrays that can perform various assays simultaneously.

Illumina, Inc. which can be found using ticker (ILMN) have now 21 analysts in total covering the stock. The consensus rating is pointing to ‘hold’. The target price High/Low ranges between $253.00 and $100.00 with the average target price sitting at $150.96. Given that the stocks previous close was at $110.53 this indicates there is a potential upside of 36.6%. Also worth taking note is the 50 day moving average now sits at $126.87 and the 200 moving average now moves to $134.77. The company has a market cap of 17.96B. The current share price for the company is: $112.77 USD

[stock_market_widget type=”chart” template=”basic” color=”green” assets=”ILMN” range=”6mo” interval=”1d” axes=”true” cursor=”true” api=”yf”]

The potential market cap would be $24,535,283,609 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of -, revenue per share of $28.39 and a -0.5% return on assets.

Illumina, Inc. is a provider of sequencing- and array-based solutions for genetic and genomic analysis. The Company operates through two segments: Core Illumina and GRAIL. Its Core Illumina segment offers products and services that serve customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. Its GRAIL segment is a healthcare company focused on early detection of multiple cancers. Its portfolio of integrated sequencing and microarray systems, consumables, and analysis tools is designed to accelerate and simplify genetic analysis. Its BaseSpace Informatics Suite integrates directly with its sequencing instruments, allowing customers to manage their biological sample and sequencing runs, process and analyze the raw genomic data, and derive results. Its BeadArray technology combines microscopic beads and a substrate in a proprietary manufacturing process to produce arrays that can perform various assays simultaneously.

Illumina, Inc. which can be found using ticker (ILMN) now have 21 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The range between the high target price and low target price is between $253.00 and $100.00 and has a mean share price target at $152.15. (at the time of writing). Given that the stocks previous close was at $124.73 this indicates there is a potential upside of 22.0%. Also worth taking note is the 50 day moving average now sits at $130.85 while the 200 day moving average is $137.96. The company has a market cap of 19.60B. The current share price for the company is: $123.05 USD

[stock_market_widget type=”chart” template=”basic” color=”green” assets=”ILMN” range=”6mo” interval=”1d” axes=”true” cursor=”true” api=”yf”]

The potential market cap would be $23,904,284,865 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of -, revenue per share of $28.51 and a -0.53% return on assets.

Illumina, Inc. is a provider of sequencing- and array-based solutions for genetic and genomic analysis. The Company operates through two segments: Core Illumina and GRAIL. Its Core Illumina segment offers products and services that serve customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. Its GRAIL segment is a healthcare company focused on early detection of multiple cancers. Its portfolio of integrated sequencing and microarray systems, consumables, and analysis tools is designed to accelerate and simplify genetic analysis. Its BaseSpace Informatics Suite integrates directly with its sequencing instruments, allowing customers to manage their biological sample and sequencing runs, process and analyze the raw genomic data, and derive results. Its BeadArray technology combines microscopic beads and a substrate in a proprietary manufacturing process to produce arrays that can perform various assays simultaneously.

Illumina, Inc. which can be found using ticker (ILMN) now have 21 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The target price High/Low ranges between $253.00 and $100.00 and has a mean target at $154.62. Given that the stocks previous close was at $117.43 this is indicating there is a potential upside of 31.7%. There is a 50 day moving average of $132.92 and the 200 moving average now moves to $139.87. The company has a market capitalization of 19.15B. The stock price for the company is currently $120.25 USD

[stock_market_widget type=”chart” template=”basic” color=”green” assets=”ILMN” range=”6mo” interval=”1d” axes=”true” cursor=”true” api=”yf”]

The potential market cap would be $25,215,336,673 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of -, revenue per share of $28.51 and a -0.53% return on assets.

Illumina, Inc. is a provider of sequencing- and array-based solutions for genetic and genomic analysis. The Company operates through two segments: Core Illumina and GRAIL. Its Core Illumina segment offers products and services that serve customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. Its GRAIL segment is a healthcare company focused on early detection of multiple cancers. Its portfolio of integrated sequencing and microarray systems, consumables, and analysis tools is designed to accelerate and simplify genetic analysis. Its BaseSpace Informatics Suite integrates directly with its sequencing instruments, allowing customers to manage their biological sample and sequencing runs, process and analyze the raw genomic data, and derive results. Its BeadArray technology combines microscopic beads and a substrate in a proprietary manufacturing process to produce arrays that can perform various assays simultaneously.

Illumina, Inc. with ticker code (ILMN) now have 21 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The target price High/Low ranges between $253.00 and $100.00 with the average target price sitting at $154.62. Given that the stocks previous close was at $127.07 this is indicating there is a potential upside of 21.7%. It’s also worth noting that there is a 50 day moving average of $135.47 and the 200 day MA is $141.57. The company has a market capitalization of 19.30B. The current share price for the company is: $121.16 USD

[stock_market_widget type=”chart” template=”basic” color=”green” assets=”ILMN” range=”6mo” interval=”1d” axes=”true” cursor=”true” api=”yf”]

The potential market cap would be $23,478,751,252 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of -, revenue per share of $28.51 and a -0.53% return on assets.

Illumina, Inc. is a provider of sequencing- and array-based solutions for genetic and genomic analysis. The Company operates through two segments: Core Illumina and GRAIL. Its Core Illumina segment offers products and services that serve customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. Its GRAIL segment is a healthcare company focused on early detection of multiple cancers. Its portfolio of integrated sequencing and microarray systems, consumables, and analysis tools is designed to accelerate and simplify genetic analysis. Its BaseSpace Informatics Suite integrates directly with its sequencing instruments, allowing customers to manage their biological sample and sequencing runs, process and analyze the raw genomic data, and derive results. Its BeadArray technology combines microscopic beads and a substrate in a proprietary manufacturing process to produce arrays that can perform various assays simultaneously.

Illumina, Inc. with ticker code (ILMN) have now 21 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The target price High/Low ranges between $258.00 and $85.00 suggesting an average analyst share price target price of $154.86. (at the time of writing). Now with the previous closing price of $127.75 this is indicating there is a potential upside of 21.2%. It’s also worth noting that there is a 50 day moving average of $137.06 while the 200 day moving average is $143.17. The total market capitalization for the company now stands at 20.72B. The current share price for the company is: $130.12 USD

[stock_market_widget type=”chart” template=”basic” color=”green” assets=”ILMN” range=”6mo” interval=”1d” axes=”true” cursor=”true” api=”yf”]

The potential market cap would be $25,119,758,737 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of -, revenue per share of $28.51 and a -0.53% return on assets.

Illumina, Inc. is a provider of sequencing- and array-based solutions for genetic and genomic analysis. The Company operates through two segments: Core Illumina and GRAIL. Its Core Illumina segment offers products and services that serve customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. Its GRAIL segment is a healthcare company focused on early detection of multiple cancers. Its portfolio of integrated sequencing and microarray systems, consumables, and analysis tools is designed to accelerate and simplify genetic analysis. Its BaseSpace Informatics Suite integrates directly with its sequencing instruments, allowing customers to manage their biological sample and sequencing runs, process and analyze the raw genomic data, and derive results. Its BeadArray technology combines microscopic beads and a substrate in a proprietary manufacturing process to produce arrays that can perform various assays simultaneously.

Illumina, Inc. which can be found using ticker (ILMN) now have 21 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The range between the high target price and low target price is between $258.00 and $85.00 suggesting an average analyst share price target price of $154.86. (at the time of writing). Given that the stocks previous close was at $132.72 this would indicate that there is a potential upside of 16.7%. The 50 day MA is $138.12 while the 200 day moving average is $142.48. The company has a market cap of 20.42B. The stock price for the company is currently is currently $128.52 USD

[stock_market_widget type=”chart” template=”basic” color=”green” assets=”ILMN” range=”6mo” interval=”1d” axes=”true” cursor=”true” api=”yf”]

The potential market cap would be $23,828,544,140 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of -, revenue per share of $28.51 and a -0.53% return on assets.

Illumina, Inc. is a provider of sequencing- and array-based solutions for genetic and genomic analysis. The Company operates through two segments: Core Illumina and GRAIL. Its Core Illumina segment offers products and services that serve customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. Its GRAIL segment is a healthcare company focused on early detection of multiple cancers. Its portfolio of integrated sequencing and microarray systems, consumables, and analysis tools is designed to accelerate and simplify genetic analysis. Its BaseSpace Informatics Suite integrates directly with its sequencing instruments, allowing customers to manage their biological sample and sequencing runs, process and analyze the raw genomic data, and derive results. Its BeadArray technology combines microscopic beads and a substrate in a proprietary manufacturing process to produce arrays that can perform various assays simultaneously.

Illumina, Inc. which can be found using ticker (ILMN) have now 21 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The target price High/Low ranges between $258.00 and $85.00 with the average share target price sitting at $154.86. (at the time of writing). Now with the previous closing price of $127.73 this is indicating there is a potential upside of 21.2%. There is a 50 day moving average of $138.42 and the 200 day MA is $148.20. The company has a market cap of 20.68B. The current share price for the company is: $130.14 USD

[stock_market_widget type=”chart” template=”basic” color=”green” assets=”ILMN” range=”6mo” interval=”1d” axes=”true” cursor=”true” api=”yf”]

The potential market cap would be $25,071,541,598 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of -, revenue per share of $28.51 and a -0.53% return on assets.

Illumina, Inc. is a provider of sequencing- and array-based solutions for genetic and genomic analysis. The Company operates through two segments: Core Illumina and GRAIL. Its Core Illumina segment offers products and services that serve customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. Its GRAIL segment is a healthcare company focused on early detection of multiple cancers. Its portfolio of integrated sequencing and microarray systems, consumables, and analysis tools is designed to accelerate and simplify genetic analysis. Its BaseSpace Informatics Suite integrates directly with its sequencing instruments, allowing customers to manage their biological sample and sequencing runs, process and analyze the raw genomic data, and derive results. Its BeadArray technology combines microscopic beads and a substrate in a proprietary manufacturing process to produce arrays that can perform various assays simultaneously.

Illumina, Inc. with ticker code (ILMN) now have 21 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The range between the high target price and low target price is between $258.00 and $85.00 calculating the average target share price we see $154.86. (at the time of writing). Given that the stocks previous close was at $139.06 this would imply there is now a potential upside of 11.4%. Also worth taking note is the 50 day moving average now sits at $138.82 and the 200 day moving average is $149.51. The company has a market cap of 21.09B. The stock price for the company is currently is currently $132.71 USD

[stock_market_widget type=”chart” template=”basic” color=”green” assets=”ILMN” range=”6mo” interval=”1d” axes=”true” cursor=”true” api=”yf”]

The potential market cap would be $23,483,594,776 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of -, revenue per share of $28.51 and a -0.53% return on assets.

Illumina, Inc. is a provider of sequencing- and array-based solutions for genetic and genomic analysis. The Company operates through two segments: Core Illumina and GRAIL. Its Core Illumina segment offers products and services that serve customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. Its GRAIL segment is a healthcare company focused on early detection of multiple cancers. Its portfolio of integrated sequencing and microarray systems, consumables, and analysis tools is designed to accelerate and simplify genetic analysis. Its BaseSpace Informatics Suite integrates directly with its sequencing instruments, allowing customers to manage their biological sample and sequencing runs, process and analyze the raw genomic data, and derive results. Its BeadArray technology combines microscopic beads and a substrate in a proprietary manufacturing process to produce arrays that can perform various assays simultaneously.

Illumina, Inc. with ticker code (ILMN) have now 21 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The target price High/Low ranges between $258.00 and $85.00 calculating the average target price we see $154.38. Given that the stocks previous close was at $139.83 and the analysts are correct then there would likely be a percentage uptick in value of 10.4%. The 50 day MA is $139.44 and the 200 day moving average is $151.91. The market cap for the company is 22.33B. The stock price is currently at: $140.50 USD

[stock_market_widget type=”chart” template=”basic” color=”green” assets=”ILMN” range=”6mo” interval=”1d” axes=”true” cursor=”true” api=”yf”]

The potential market cap would be $24,648,523,830 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of -, revenue per share of $28.51 and a -0.53% return on assets.

Illumina, Inc. is a provider of sequencing- and array-based solutions for genetic and genomic analysis. The Company operates through two segments: Core Illumina and GRAIL. Its Core Illumina segment offers products and services that serve customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. Its GRAIL segment is a healthcare company focused on early detection of multiple cancers. Its portfolio of integrated sequencing and microarray systems, consumables, and analysis tools is designed to accelerate and simplify genetic analysis. Its BaseSpace Informatics Suite integrates directly with its sequencing instruments, allowing customers to manage their biological sample and sequencing runs, process and analyze the raw genomic data, and derive results. Its BeadArray technology combines microscopic beads and a substrate in a proprietary manufacturing process to produce arrays that can perform various assays simultaneously.

Illumina, Inc. which can be found using ticker (ILMN) now have 21 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The range between the high target price and low target price is between $258.00 and $85.00 and has a mean target at $154.38. Now with the previous closing price of $133.00 this now indicates there is a potential upside of 16.1%. It’s also worth noting that there is a 50 day moving average of $138.12 while the 200 day moving average is $153.55. The company has a market capitalization of 21.76B. The current share price for the company is: $136.97 USD

[stock_market_widget type=”chart” template=”basic” color=”green” assets=”ILMN” range=”6mo” interval=”1d” axes=”true” cursor=”true” api=”yf”]

The potential market cap would be $25,263,221,690 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of -, revenue per share of $28.51 and a -0.53% return on assets.

Illumina, Inc. is a provider of sequencing- and array-based solutions for genetic and genomic analysis. The Company operates through two segments: Core Illumina and GRAIL. Its Core Illumina segment offers products and services that serve customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. Its GRAIL segment is a healthcare company focused on early detection of multiple cancers. Its portfolio of integrated sequencing and microarray systems, consumables, and analysis tools is designed to accelerate and simplify genetic analysis. Its BaseSpace Informatics Suite integrates directly with its sequencing instruments, allowing customers to manage their biological sample and sequencing runs, process and analyze the raw genomic data, and derive results. Its BeadArray technology combines microscopic beads and a substrate in a proprietary manufacturing process to produce arrays that can perform various assays simultaneously.

Illumina, Inc. with ticker code (ILMN) have now 21 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The range between the high target price and low target price is between $258.00 and $85.00 and has a mean share price target at $152.81. (at the time of writing). Now with the previous closing price of $146.07 this would indicate that there is a potential upside of 4.6%. Also worth taking note is the 50 day moving average now sits at $136.45 and the 200 day moving average is $154.77. The company has a market capitalization of 22.79B. The stock price for the company is currently is currently $143.41 USD

[stock_market_widget type=”chart” template=”basic” color=”green” assets=”ILMN” range=”6mo” interval=”1d” axes=”true” cursor=”true” api=”yf”]

The potential market cap would be $23,839,333,163 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of -, revenue per share of $28.51 and a -0.53% return on assets.

Illumina, Inc. is a provider of sequencing- and array-based solutions for genetic and genomic analysis. The Company operates through two segments: Core Illumina and GRAIL. Its Core Illumina segment offers products and services that serve customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. Its GRAIL segment is a healthcare company focused on early detection of multiple cancers. Its portfolio of integrated sequencing and microarray systems, consumables, and analysis tools is designed to accelerate and simplify genetic analysis. Its BaseSpace Informatics Suite integrates directly with its sequencing instruments, allowing customers to manage their biological sample and sequencing runs, process and analyze the raw genomic data, and derive results. Its BeadArray technology combines microscopic beads and a substrate in a proprietary manufacturing process to produce arrays that can perform various assays simultaneously.

Illumina, Inc. with ticker code (ILMN) now have 21 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The target price High/Low ranges between $258.00 and $85.00 calculating the mean target share price we have $152.81. (at the time of writing). Now with the previous closing price of $139.96 this now indicates there is a potential upside of 9.2%. Also worth taking note is the 50 day moving average now sits at $133.93 and the 200 moving average now moves to $155.98. The market capitalization for the company is 21.35B. The stock price for the company is currently $134.43 USD

[stock_market_widget type=”chart” template=”basic” color=”green” assets=”ILMN” range=”6mo” interval=”1d” axes=”true” cursor=”true” api=”yf”]

The potential market cap would be $23,307,437,670 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of -, revenue per share of $28.51 and a 0.11% return on assets.

Illumina, Inc. is a provider of sequencing- and array-based solutions for genetic and genomic analysis. The Company operates through two segments: Core Illumina and GRAIL. Its Core Illumina segment offers products and services that serve customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. Its GRAIL segment is a healthcare company focused on early detection of multiple cancers. Its portfolio of integrated sequencing and microarray systems, consumables, and analysis tools is designed to accelerate and simplify genetic analysis. Its BaseSpace Informatics Suite integrates directly with its sequencing instruments, allowing customers to manage their biological sample and sequencing runs, process and analyze the raw genomic data, and derive results. Its BeadArray technology combines microscopic beads and a substrate in a proprietary manufacturing process to produce arrays that can perform various assays simultaneously.

Illumina, Inc. with ticker code (ILMN) have now 22 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The range between the high target price and low target price is between $258.00 and $80.00 calculating the mean target share price we have $143.64. (at the time of writing). Given that the stocks previous close was at $144.21 this indicates there is a potential downside of -.4%. Also worth taking note is the 50 day moving average now sits at $129.53 and the 200 moving average now moves to $158.00. The market capitalization for the company is 22.59B. The stock price for the company is currently $142.23 USD

[stock_market_widget type=”chart” template=”basic” color=”green” assets=”ILMN” range=”6mo” interval=”1d” axes=”true” cursor=”true” api=”yf”]

The potential market cap would be $22,496,851,069 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of -, revenue per share of $28.30 and a -0.65% return on assets.

Illumina, Inc. is a provider of sequencing- and array-based solutions for genetic and genomic analysis. The Company operates through two segments: Core Illumina and GRAIL. Its Core Illumina segment offers products and services that serve customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. Its GRAIL segment is a healthcare company focused on early detection of multiple cancers. Its portfolio of integrated sequencing and microarray systems, consumables, and analysis tools is designed to accelerate and simplify genetic analysis. Its BaseSpace Informatics Suite integrates directly with its sequencing instruments, allowing customers to manage their biological sample and sequencing runs, process and analyze the raw genomic data, and derive results. Its BeadArray technology combines microscopic beads and a substrate in a proprietary manufacturing process to produce arrays that can perform various assays simultaneously.

Illumina, Inc. with ticker code (ILMN) now have 22 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The target price High/Low ranges between $258.00 and $80.00 and has a mean share price target at $143.64. (at the time of writing). Now with the previous closing price of $146.72 this would imply there is a potential downside of -2.1%. It’s also worth noting that there is a 50 day moving average of $124.75 and the 200 day moving average is $160.14. The company has a market capitalization of 23.15B. The current share price for the company is: $145.76 USD

[stock_market_widget type=”chart” template=”basic” color=”green” assets=”ILMN” range=”6mo” interval=”1d” axes=”true” cursor=”true” api=”yf”]

The potential market cap would be $22,660,782,741 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of -, revenue per share of $28.30 and a -0.65% return on assets.

Illumina, Inc. is a provider of sequencing- and array-based solutions for genetic and genomic analysis. The Company operates through two segments: Core Illumina and GRAIL. Its Core Illumina segment offers products and services that serve customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. Its GRAIL segment is a healthcare company focused on early detection of multiple cancers. Its portfolio of integrated sequencing and microarray systems, consumables, and analysis tools is designed to accelerate and simplify genetic analysis. Its BaseSpace Informatics Suite integrates directly with its sequencing instruments, allowing customers to manage their biological sample and sequencing runs, process and analyze the raw genomic data, and derive results. Its BeadArray technology combines microscopic beads and a substrate in a proprietary manufacturing process to produce arrays that can perform various assays simultaneously.

Illumina, Inc. with ticker code (ILMN) have now 22 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The range between the high target price and low target price is between $258.00 and $50.00 calculating the average target price we see $140.68. Given that the stocks previous close was at $135.88 this would indicate that there is a potential upside of 3.5%. The 50 day moving average now sits at $120.15 and the 200 day moving average is $162.76. The market cap for the company is 22.05B. The stock price is currently at: $138.88 USD

[stock_market_widget type=”chart” template=”basic” color=”green” assets=”ILMN” range=”6mo” interval=”1d” axes=”true” cursor=”true” api=”yf”]

The potential market cap would be $22,833,212,967 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of -, revenue per share of $28.30 and a -0.65% return on assets.

Illumina, Inc. is a provider of sequencing- and array-based solutions for genetic and genomic analysis. The Company operates through two segments: Core Illumina and GRAIL. Its Core Illumina segment offers products and services that serve customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. Its GRAIL segment is a healthcare company focused on early detection of multiple cancers. Its portfolio of integrated sequencing and microarray systems, consumables, and analysis tools is designed to accelerate and simplify genetic analysis. Its BaseSpace Informatics Suite integrates directly with its sequencing instruments, allowing customers to manage their biological sample and sequencing runs, process and analyze the raw genomic data, and derive results. Its BeadArray technology combines microscopic beads and a substrate in a proprietary manufacturing process to produce arrays that can perform various assays simultaneously.

Illumina, Inc. which can be found using ticker (ILMN) now have 22 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The target price High/Low ranges between $258.00 and $50.00 calculating the mean target price we have $138.08. Given that the stocks previous close was at $130.48 this indicates there is a potential upside of 5.8%. The day 50 moving average is $115.92 and the 200 day moving average is $166.16. The total market capitalization for the company now stands at 21.23B. The stock price for the company is currently $133.66 USD

[stock_market_widget type=”chart” template=”basic” color=”green” assets=”ILMN” range=”6mo” interval=”1d” axes=”true” cursor=”true” api=”yf”]

The potential market cap would be $22,461,501,335 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of -, revenue per share of $28.30 and a -0.65% return on assets.

Illumina, Inc. is a provider of sequencing- and array-based solutions for genetic and genomic analysis. The Company operates through two segments: Core Illumina and GRAIL. Its Core Illumina segment offers products and services that serve customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. Its GRAIL segment is a healthcare company focused on early detection of multiple cancers. Its portfolio of integrated sequencing and microarray systems, consumables, and analysis tools is designed to accelerate and simplify genetic analysis. Its BaseSpace Informatics Suite integrates directly with its sequencing instruments, allowing customers to manage their biological sample and sequencing runs, process and analyze the raw genomic data, and derive results. Its BeadArray technology combines microscopic beads and a substrate in a proprietary manufacturing process to produce arrays that can perform various assays simultaneously.